This press release contains certain forward-looking statements relating to our business, including our plans to develop and commercialize DNA medicines and expectations regarding our research and development programs, including the planned submission of a BLA in the second half of 2024 and the planned commercial launch of INO-3107 if regulatory approval is obtained. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent ...

The stock option has an exercise price of $8.08, which is equal to the closing price of INOVIO's common stock on June 28, 2024. The stock option will vest and become exercisable with respect to one-fourth of the shares underlying the stock option on the Grant Date, and an additional one-fourth of the shares underlying the stock option on the first, second, and third anniversaries of the Grant Date. The vesting of the stock option will be subject to the employee's continued employment with INOVIO on the appl ...

For more information on the Russell 3000® Index and the Russell indexes reconstitution, visit the "Russell Reconstitution" section on the FTSE Russell website. FTSE Russell is a leading global provider of benchmarking, analytics, and data solutions for investors, giving them a precise view of the market relevant to their investment process. A comprehensive range of reliable and accurate indexes provides investors worldwide with the tools they require to measure and benchmark markets across asset classes, st ...

PLYMOUTH MEETING, Pa., June 4, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that INOVIO's President and CEO, Dr. Jacqueline Shea, and Chief Medical Officer, Dr. Michael Sumner will participate in a virtual fireside chat hosted by Sudan Loganathan, Ph.D., Managing Director and equity research analyst at Stephens, Inc. The f ...

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease- fighting tools. For more information, visit www.inovio.com. Contacts Media: Jennie Willson, (267) 429-8567, [email protected] Investors: Thomas Hong, (267) 440-4298, [email protected] SOURCE INOV ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) H.C. Wainwright 2nd Annual BioConnect Investor Conference Call May 20, 2024 12:30 PM ET Company Participants Jacqueline Shea - President & Chief Executive Officer Michael Sumner - Chief Medical Officer Unidentified Analyst Welcome to the H.C. Wainwright 2nd Annual BioConnect Investor Conference at Nasdaq. For this session, we are glad to have Ms. Jacqueline Shea, President and CEO of Inovio, and Mr. Michael Sumner, Chief Medical Officer of Inovio [indiscernible]. We ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) RBC Capital Markets Global Healthcare Conference May 15, 2024 10:00 AM ET Company Participants Jacqueline Shea - CEO Mike Sumner - Chief Medical Officer Conference Call Participants Gregory Renza - Biotechnology Equity Research Analyst, RBC Gregory Renza Let's get started and welcome back everyone to the 2024 RBC Global Health Care Conference. My name is Greg Renza, one of the Biotechnology Research Analyst here at RBC and we're pleased to be joined with Inovio Phar ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) The Citizens JMP Life Sciences Conference May 14, 2024 11:30 AM ET Company Participants Jacqueline Shea - CEO Conference Call Participants Roy Buchanan - Citizens JMP Roy Buchanan Everybody again for joining Citizens JMP Life Science Conference. My name's Roy Buchanan, I'm a biotech research analyst. And we're happy to have Inovio Pharmaceuticals here with us. And we've got Jackie Shea, she's the Chief Executive Officer. So certainly exciting time at Inovio. Earning ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Mark Twyman - Chief Commercial Officer Peter Kies - Chief Financial Officer Conference Call Participants Hartaj Singh - Oppenheimer Roy Buchanan - JMP Anish Nikhanj - RBC Capital Markets Roger Song - Jefferies Yi Chen - H.C. Wainwright Operator Good aft ...

| --- | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------| | | | | | as throat cancer | | | | Occurs in the base of the tongue, tonsils and/or soft palate | | | | Typically causally related to high-risk subtypes of HPV, some cases are carcinogen-driven | | | | HPV+ throat cancer rapidly increasing in incidence | | | | among patients in high-income countries ◦ Surpassed cervical ...